Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
February 2016 Vol 9, Special Issue: Payers' Perspectives in Oncology
Leukemia
Nilotinib Yields Better Rates of Molecular Response Than Imatinib in Frontline Setting
Chase Doyle
Read More
Leukemia
Ibrutinib a New Standard of Care for Elderly Patients with Chronic Lymphocytic Leukemia
Phoebe Starr
Read More
Leukemia
Idelalisib Improves Survival When Added to Bendamustine plus Rituximab in Patients with CLL
Phoebe Starr
Read More
Leukemia
Immunotherapy with Blinatumomab Prolongs Survival in Acute Lymphoblastic Leukemia
Chase Doyle
Read More
Emerging Therapies
The Hematologic Drug Pipeline: Exciting New Treatment Options Looming
Phoebe Starr
Read More
Emerging Therapies
Midostaurin the First Targeted Therapy to Improve Survival in AML: Potentially Practice-Changing
Phoebe Starr
Read More
Emerging Therapies
Venetoclax Shows Strong Activity in CLL
Phoebe Starr
Read More
Value-Based Care Must Be Linked to Improved Clinical Outcomes
James T. Kenney, RPh, MBA
Read More
1
2
Page 2 of 2
Results 11 - 18 of 18